[01] Nenfa Solomon Monday, Department of Obstetrics and Gynaecology, Jos University Teaching Hospital, Jos, Nigeria; Centre for Research, Institute of Medical Sciences Africa, Abuja, Nigeria. [02] Iornum Hembe Shambe, Department of Obstetrics and Gynaecology, Jos University Teaching Hospital, Jos, Nigeria. [03] Stephen Anzaku, Department of Obstetrics and Gynaecology, Bingham University Teaching Hospital, Nasarawa, Nigeria. [04] Patrick Haruna Daru, Department of Obstetrics and Gynaecology, Jos University Teaching Hospital, Jos, Nigeria. [05] Stephen Stephen Hati, Centre for Research, Institute of Medical Sciences Africa, Abuja, Nigeria.

The aim of the study was to determine the relationship between age at coitarche and cervical intraepithelial changes in Jos University Teaching Hospital. This was a cross-sectional study comprising 120 women with abnormal and 120 women with normal Pap smear results selected by systematic sampling after obtaining consent. Data were analysed with Epi-info 3.5.2 statistical software. Chi-square test compared categorical variables, Student’s T-test compared means, while logistic regression was used to assess the interaction between independent and the leading independent variable The level of statistical significance was <0.05. Results show that the average age at coitarche of the study population was 19.7 years. Women with abnormal Pap smears had a lower mean age at coitarche (about 18 years) than those with normal Pap smears (about 21 years), and this was statistically significant (P<0.001). While ASC-US was the most frequent abnormality found (42.4%), HSIL was the least (4.2%). Women who attained coitarche at age less than 18 years were six times more likely to develop an abnormality. It was concluded that the age at coitarche was low and that having sexual debut at a much younger age is an independent risk factor for the development of squamous intraepithelial lesion.

Age, Coitarche, Cervical Intraepithelial Changes

[01] Revzina N V, DiClemente RJ. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. Int J STD AIDS. 2005; 16 (8): 528–37. [02] Liu G, Sharma M, Tan N, Barnabas R V. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018; 32 (6): 795–808. [03] Agorastos T, Miliaras D, Lambropoulos AF, Chrisafi S, Kotsis A, Manthos A, et al. Detection and typing of human papillomavirus DNA in uterine cervices with coexistent grade I and grade III intraepithelial neoplasia: biologic progression or independent lesions? Eur J Obstet Gynecol Reprod Biol. 2005; 121 (1): 99–103. [04] Senkomago V, Sangrajrang S, Ketgudee L, Saraiya M. Challenges in educating women about human papillomavirus (HPV) and HPV screening test results: Experience from an HPV demonstration project in North-Eastern Thailand. Papillomavirus Res. 2016; 2: 190–2. [05] Holschneider CH. Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis - UpToDate. In: Goff B, editor. Uptodate. 2009. [06] Holschneider CH. Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis. In: Goff B, editor. Uptodate. 2009. [07] Li W, Shi D, Jia R, Yang J, Zhang Y, Chen W, et al. Selection of DNA aptamers to cervical intraepithelial neoplasia by SELEX. Sheng Wu Gong Cheng Xue Bao. 2018; 34 (5): 785–93. [08] Devesa SS. Descriptive Epidemiology of Cancer of the Uterine Cervix. Obs Gynecol. 1984; 63 (12): 605–612. [09] Dickson N, Paul C, Herbison P, Silva P. First sexual intercourse: age, coercion, and later regrets reported by a birth cohort. BMJ. 1998; 316 (7124): 29–33. [10] Kamwendo F, Forslin L, Bodin L, Danielsson D. Decreasing incidences of gonorrhea- and chlamydia-associated acute pelvic inflammatory disease. A 25-year study from an urban area of central Sweden. Sex Transm Dis. 23 (5): 384–91. [11] Reeves WC, Caussy D, Brinton LA, Brenes MM, Montalvan P, Gomez B, et al. Case-control study of human papillomaviruses and cervical cancer in Latin America. Int J cancer. 1987; 40 (4): 450–4. [12] Slattery ML, Overall JC, Abbott TM, French TK, Robison LM, Gardner J. Sexual activity, contraception, genital infections, and cervical cancer: support for a sexually transmitted disease hypothesis. Am J Epidemiol. 1989; 130 (2): 248–58. [13] Cuzick J, De Stavola B, McCance D, Ho TH, Tan G, Cheng H, et al. A case-control study of cervix cancer in Singapore. Br J Cancer. 1989; 60 (2): 238–43. [14] Zaninetti P, Franceschi S, Baccolo M, Bonazzi B, Gottardi G, Serraino D. Characteristics of women under 20 with cervical intraepithelial neoplasia. Int J Epidemiol. 1986; 15 (4): 477–82. [15] NPC & ICF International. Nigeria Demographic and Health Survey (NDHS) 2013. National Population Commission (NPC) Abuja, Nigeria, and ICF International Rockville, Maryland, USA. 2014. [16] Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah K V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55 (4): 244–65. [17] Chetty R. 70 years of the JCP-highly cited papers: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2017; 70 (12): 997–997. [18] Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, Unger ER, et al. Seroprevalence of Human Papillomavirus Type 16 Infection in the United States. J Infect Dis. 2002; 186 (10): 1396–402. [19] Araoye MO. Research Methodology with Statistics for Health and Social Sciences. 1st ed. Nathadex Publishers Ilorin. Illorin: Nathadex; 2004. 25-120 p. [20] Obafunwa J. O., Sagay A. S. OJAM. Prevalence of Cervical Intraepithelial Neoplasia in Jos, Nigeria. Trop J Obstet Gynaecol. 1991; 9 (2): 16-17. [21] Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998; 132 (2): 277–84. [22] Andersson-Ellström A, Forssman L, Milsom I. Age of sexual debut related to life-style and reproductive health factors in a group of Swedish teenage girls. Acta Obstet Gynecol Scand. 1996; 75 (5): 484–9. [23] Cyrus-David MS, Michielutte R, Paskett ED, D’Agostino R, Goff D. Cervical cancer risk as a predictor of Pap smear use in rural North Carolina. J Rural Health. 2002; 18 (1): 67–76. [24] Balaha M, Al Ghowinem N, Al Moghannum M, Al Omran S. Cytological pattern of cervical papanicolaou smear in eastern region of Saudi Arabia. J Cytol. 2011; 28 (4): 173. [25] Gupta S, Sodhani P, Halder K, Chachra KL, Sardana S, Singh V, et al. Spectrum of epithelial cell abnormalities of uterine cervix in a cervical cancer screening programme: Implications for resource limited settings. Eur J Obstet Gynecol Reprod Biol. 2007; 134 (2): 238–42. [26] Deshou H, Changhua W, Qinyan L, Wei L, Wen F. Clinical utility of Liqui-PREPTM cytology system for primary cervical cancer screening in a large urban hospital setting in China. J Cytol. 2009; 26 (1): 20–5. [27] Arbyn M, Van Nieuwenhuyse A, Bogers J, De Jonge E, De Beeck LO, Matheï C, et al. Cytological screening for cervical cancer in the province of Limburg, Belgium. Eur J Cancer Prev. 2011; 20 (1): 18–24. [28] Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: A population-based study. Am J Obstet Gynecol. 2004; 191 (1): 105–13. [29] Păvăleanu I, Gafiţanu D, Ioanid N, Grigore M. Preliminary results of the first cervical cancer screening programme in the North Eastern region of Romania. J Med Screen. 2018; 096914131775346. [30] Castellsagué X, Muñoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003; (31): 20–8. [31] Yeo-Teh N, Ito Y, Jha S. High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis. Int J Mol Sci. 2018; 19 (6): 1706.